Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Published in Annals of oncology : official journal of the European Society for Medical Oncology • Oct 1, 2019
Authors:,,
J M Weiss
T Csoszi
M Maglakelidze
Abstract
BACKGROUND: Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation). Preclinicall...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!